PDEX vs. NVNO, MGRM, SEPA, STIM, HSAQ, NSPR, DRIO, ICCM, AMIX, and APYX
Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), SEP Acquisition (SEPA), Neuronetics (STIM), Health Sciences Acquisitions Co. 2 (HSAQ), InspireMD (NSPR), DarioHealth (DRIO), IceCure Medical (ICCM), Autonomix Medical (AMIX), and Apyx Medical (APYX). These companies are all part of the "surgical & medical instruments" industry.
Pro-Dex (NASDAQ:PDEX) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 42.6% of Pro-Dex shares are owned by insiders. Comparatively, 17.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Pro-Dex had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for Pro-Dex and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 1.63 beat Pro-Dex's score of 1.59 indicating that enVVeno Medical is being referred to more favorably in the news media.
Pro-Dex has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Pro-Dex has a net margin of 4.13% compared to enVVeno Medical's net margin of 0.00%. Pro-Dex's return on equity of 6.50% beat enVVeno Medical's return on equity.
enVVeno Medical received 10 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 62.65% of users gave enVVeno Medical an outperform vote while only 60.58% of users gave Pro-Dex an outperform vote.
Pro-Dex has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Summary
Pro-Dex beats enVVeno Medical on 9 of the 14 factors compared between the two stocks.
Get Pro-Dex News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
